BridgeBio Oncology Therapeutics (BBOT)
Eli Wallace is an experienced executive in the biotechnology industry, currently serving as Chief Executive Officer at BridgeBio Oncology Therapeutics since May 2024. Previously, Eli held several leadership roles at BridgeBio, including Chief Executive Officer of Oncology R&D and Chief Scientific Officer In Residence from December 2019 to April 2024. Eli's career includes significant positions at Peloton Therapeutics, where responsibilities included Chief Scientific Officer, Vice President of Chemistry, and Director of Medicinal Chemistry from October 2011 to December 2019. Prior to that, Eli was Director of Medicinal Chemistry at Array BioPharma and worked as a Research Scientist at Glaxo Wellcome. Eli earned a Ph.D. in Synthetic Organic Chemistry from Colorado State University between 1990 and 1993.
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.